Substance use screening in a primary care setting compared the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST version 3.0), Two-Item Conjoint Screen (TICS), National Institute on Alcohol Abuse and Alcoholism (NIAAA) daily limit single item, and electronic medical record (EMR). Among 236 consecutive adults, ASSIST moderate- to high-risk substance use prevalence was tobacco, 15.3%; alcohol, 8.5%; cannabis, 5.1%; cocaine, 2.5%; and opioids, 2.5%. Compared to ASSIST, a positive TICS was 45% (95% confidence interval [CI], 27–64%) sensitive, 99% (95–100%) specific; the NIAAA single-item screen was 80% (56–94%) sensitive, 87% (82–91%) specific. The NIAAA single item correlated closely with alcohol ASSIST. TICS and EMR were less sensitive for any nontobacco substance use.
Substance Abuse and Mental Health Services Administration. 2008. Results From the 2007 National Survey on Drug Use and Health: National Findings, NSDUH Series H-34, DHHS Publication No. SMA 08-4343Rockville, MD: Office of Applied Studies.
2.
ComptonW M, ThomasY F, StinsonF S and GrantB F. 2007. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry., 64: 566–576.
3.
US Preventive Services Task Force. 2004. Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse, Rockville, MD: Agency for Healthcare Research and Quality.
4.
Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. 2007. “Screening, brief intervention, and referral to treatment”. Available at: http://sbirt.samhsa.gov/. Accessed May 1, 2009
5.
National Institute of Drug Abuse. 2009. “Screening for drug use in general medical settings: a resource guide for providers”. Available at: http://www.nida.nih.gov/nidamed/screening/. Accessed May 1, 2009
6.
BaborT F, McReeB G, KassebaumP A, GrimaldiP L, AhmedK and BrayJ. 2007. Screening, brief intervention, and referral to treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abuse., 28: 7–30.
7.
MadrasB K, ComptonW M, AvulaD, StegbauerT, SteinJ B and ClarkH W. 2009. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend., 99: 280–295.
8.
HumeniukR. 2008. The Effectiveness of a Brief Intervention for Illicit Drugs Linked to the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) in Primary Health Care Settings: A Technical Report of Phase III Findings of the WHO ASSIST Randomized Control Trial, Geneva: World Health Organization. Available at: http://www.who.int/substance_abuse/activities/assist_technicalreport_phase3_final.pdf. Accessed November 13, 2009
9.
US Preventive Services Task Force. 2008. Screening for Illicit Drug Use, Rockville, MD: Agency for Healthcare Research and Quality.
10.
National Association of Public Hospitals and Health Systems (NAPH). 2004. America's Public Hospitals and Health Systems, 2004, Washington, DC: NAPH. Available at: http://www.naph.org/naph/publications/Survey2004.pdf
11.
WHO ASSIST Working Group. 2002. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction, 97: 1183–1194.
12.
HenryEdwards S, HumeniukR, AliR, PoznyakV and MonteiroM. 2008. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Guidelines for Use in Primary Care, Geneva: World Health Organization (WHO).
13.
NewcombeD, HumeniukR and AliR. 2005. Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. Drug Alcohol Rev., 24: 217–226.
14.
HumeniukR, AliRBaborT F. 2008. Validation of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Addiction, 103: 1039–1047.
15.
National Institute on Alcohol Abuse and Alcoholism. 2007. Helping Patients Who Drink Too Much: A Clinician's Guide, Updated 2005 Edition, NIH Publication No. 07-3769Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism.
16.
BrownR L, LeonardT, SaundersL and PapasouliotisO. 2001. A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract., 14: 95–106.
17.
McLellanA T, AltermanA I, CacciolaJ, MetzgerD and O'BrienC P. 1992. A new measure of substance abuse treatment: initial studies of the Treatment Services Review. J Nerv Ment Dis., 180: 101–110.
18.
WalleyA Y, FarrarD, ChengD M, AlfordD P and SametJ H. 2009. Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue. J Gen Intern Med., 24: 1007–1011.
19.
SpearS, ShannonS, Gong-GuyE and RawsonR. 2009. Substance abuse screening in the 21st century: a pilot study of a computerized, self-administered ASSIST [abstract]. Presented at the American Society of Addiction Medicine 40th Annual Medical-Scientific Conference. 2009, New Orleans, LA. May 2
20.
BradleyK A, WilliamsE C, AchtmeyerC E, VolppB, CollinsB J and KivlahanD R. 2006. Implementation of evidence-based alcohol screening in the Veterans Health Administration. Am J Manag Care., 12: 597–606.
21.
BradleyK A, WilliamsE CAchtmeyerC E. 2007. Measuring performance of brief alcohol counseling in medical settings: a review of the options and lessons from the Veterans Affairs (VA) health care system. Subst Abuse, 28: 133–149.
22.
US Preventive Services Task Force. 2003. Counseling to Prevent Tobacco Use and Tobacco-Related Diseases: Recommendation Statement, Rockville, MD: Agency for Healthcare Research and Quality.
23.
PettinatiH M, GastfriendD R, DongQ, KranzlerH R and O'MalleyS S. 2009. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res., 33: 350–356.
24.
JohnsonB A, RosenthalNCapeceJ A. 2007. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA, 298: 1641–1651.
25.
AntonR F, O'MalleyS SCirauloD A. 2006. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA, 295: 2003–2017.
26.
SpillerH, LorenzD J, BaileyE J and DartR C. 2009. Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis., 2: 130–136.
27.
VanZee A. 2009. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health, 99: 221–227.
28.
Center for Substance Abuse Treatment. 2004. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol (TIP) Series 40, Rockville, MD: Substance Abuse and Mental Health Services Administration.
29.
FiellinD A, MooreB ASullivanL E. 2008. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict, 17: 116–120.
30.
LeeJ D, GrossmanE, DiRoccoD and GourevitchM N. 2009. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med., 24: 226–232.
31.
SmithP C, SchmidtS M, Allensworth-DaviesD and SaitzR. 2009. Primary care validation of a single-question alcohol screening test. J Gen Intern Med., 24: 783–788.
